{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T23:18:53Z","timestamp":1794093533934,"version":"4.8.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802126"],"award-info":[{"award-number":["81802126"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802126"],"award-info":[{"award-number":["81802126"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802126"],"award-info":[{"award-number":["81802126"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802126"],"award-info":[{"award-number":["81802126"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802126"],"award-info":[{"award-number":["81802126"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802126"],"award-info":[{"award-number":["81802126"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802126"],"award-info":[{"award-number":["81802126"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802126"],"award-info":[{"award-number":["81802126"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802126"],"award-info":[{"award-number":["81802126"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03623-7","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T10:46:38Z","timestamp":1765190798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mutant IL-2-expressing mesenchymal stromal cells promote regulatory T cells proliferation and activation in collagen induced arthritis mice"],"prefix":"10.1186","volume":"28","author":[{"given":"Zhicheng","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiming","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanzhang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"issue":"10055","key":"3623_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. The Lancet. 2016;388(10055):2023\u201338.","journal-title":"The Lancet"},{"key":"3623_CR2","doi-asserted-by":"crossref","unstructured":"Lin, Y.J., M. Anzaghe and S. Schulke, Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. Cells, 2020. 9(4).","DOI":"10.3390\/cells9040880"},{"key":"3623_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.572858","volume":"11","author":"A Paradowska-Gorycka","year":"2020","unstructured":"Paradowska-Gorycka A, et al. Th17\/Treg-Related Transcriptional Factor Expression and Cytokine Profi le in Patients With Rheumatoid Arthritis. Front Immunol. 2020;11: 572858.","journal-title":"Front Immunol"},{"issue":"10","key":"3623_CR4","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/intimm\/dxp095","volume":"21","author":"S Sakaguchi","year":"2009","unstructured":"Sakaguchi S, et al. Regulatory T cells: how do they suppress immune responses? Int Immunol. 2009;21(10):1105\u201311.","journal-title":"Int Immunol"},{"key":"3623_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.626193","volume":"12","author":"Q Jiang","year":"2021","unstructured":"Jiang Q, et al. Function and Role of Regulatory T Cells in Rheumatoid Arthritis. Front Immunol. 2021;12: 626193.","journal-title":"Front Immunol"},{"key":"3623_CR6","doi-asserted-by":"publisher","first-page":"1104881","DOI":"10.3389\/fimmu.2023.1104881","volume":"14","author":"Y Hu","year":"2023","unstructured":"Hu Y, et al. Hypermethylation of Smad7 in CD4(+) T cells is associated with the disease activity of rheumatoid arthritis. Front Immunol. 2023;14:1104881.","journal-title":"Front Immunol"},{"key":"3623_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-8802-0_1","volume":"1868","author":"M Miyoshi","year":"2018","unstructured":"Miyoshi M, Liu S. Collagen-Induced Arthritis Models. Methods Mol Biol. 2018;1868:3\u20137.","journal-title":"Methods Mol Biol"},{"key":"3623_CR8","first-page":"1","volume":"2015","author":"X Liu","year":"2015","unstructured":"Liu X, et al. Human Umbilical Cord Mesenchymal Stem Cells Inhibit the Function of Allogeneic Activated V\u03b3 9V\u03b4 2 T Lymphocytes In Vitro. Biomed Res Int. 2015;2015:1\u201310.","journal-title":"Biomed Res Int"},{"issue":"3","key":"3623_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/scrt216","volume":"4","author":"P Luz-Crawford","year":"2013","unstructured":"Luz-Crawford P, et al. Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther. 2013;4(3):65.","journal-title":"Stem Cell Res Ther"},{"key":"3623_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121474","volume":"283","author":"Y Lu","year":"2022","unstructured":"Lu Y, et al. Highly effective rheumatoid arthritis therapy by peptide-promoted nanomodification of mesenchymal stem cells. Biomaterials. 2022;283: 121474.","journal-title":"Biomaterials"},{"issue":"21","key":"3623_CR11","doi-asserted-by":"publisher","first-page":"11592","DOI":"10.3390\/ijms222111592","volume":"22","author":"M Sarsenova","year":"2021","unstructured":"Sarsenova M, et al. Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis. Int J Mol Sci. 2021;22(21):11592.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"3623_CR12","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/stcltm\/szad065","volume":"12","author":"D Tsiapalis","year":"2023","unstructured":"Tsiapalis D, et al. Therapeutic Effects of Mesenchymal\/Stromal Stem Cells and Their Derived Extracellular Vesicles in Rheumatoid Arthritis. Stem Cells Transl Med. 2023;12(12):849\u201362.","journal-title":"Stem Cells Transl Med"},{"issue":"3","key":"3623_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.stem.2009.02.001","volume":"4","author":"JM Karp","year":"2009","unstructured":"Karp JM, Leng TG. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;4(3):206\u201316.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"3623_CR14","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3892\/etm.2021.10707","volume":"22","author":"L An","year":"2021","unstructured":"An L, et al. Frequent injections of high-dose human umbilical cord mesenchymal stem cells slightly aggravate arthritis and skeletal muscle cachexia in collagen-induced arthritic mice. Exp Ther Med. 2021;22(5):1272.","journal-title":"Exp Ther Med"},{"key":"3623_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1146\/annurev.immunol.26.021607.090357","volume":"26","author":"TR Malek","year":"2008","unstructured":"Malek TR. The biology of interleukin-2. Annu Rev Immunol. 2008;26:453\u201379.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"3623_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1586\/1744666X.2014.875856","volume":"10","author":"D Skrombolas","year":"2014","unstructured":"Skrombolas D, Frelinger JG. Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy. Expert Rev Clin Immunol. 2014;10(2):207\u201317.","journal-title":"Expert Rev Clin Immunol"},{"issue":"12","key":"3623_CR17","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1517\/14712598.6.12.1323","volume":"6","author":"O Boyman","year":"2006","unstructured":"Boyman O, Surh CD, Sprent J. Potential use of IL-2\/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin Biol Ther. 2006;6(12):1323\u201331.","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"3623_CR18","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1200\/JCO.1991.9.4.694","volume":"9","author":"JP Siegel","year":"1991","unstructured":"Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol. 1991;9(4):694\u2013704.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3623_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2019","unstructured":"He J, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2019;79(1):141\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3623_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41392-022-00887-2","volume":"7","author":"X Zhang","year":"2022","unstructured":"Zhang X, et al. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2022;7(1):67.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3623_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","volume":"38","author":"W Liao","year":"2013","unstructured":"Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013;38(1):13\u201325.","journal-title":"Immunity"},{"key":"3623_CR22","doi-asserted-by":"crossref","unstructured":"Nelson, B.H., IL-2, regulatory T cells, and tolerance. Journal of immunology (Baltimore, Md. : 1950), 2004. 172(7): p. 3983\u20138.","DOI":"10.4049\/jimmunol.172.7.3983"},{"key":"3623_CR23","doi-asserted-by":"crossref","unstructured":"Robb, R.J., A. Munck and K.A. Smith, T cell growth factor receptors. Quantitation, specificity, and biologi cal relevance. The Journal of experimental medicine, 1981. 154(5): p. 1455\u201374.","DOI":"10.1084\/jem.154.5.1455"},{"issue":"6","key":"3623_CR24","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1084\/jem.20182304","volume":"216","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, et al. Human interleukin-2 receptor \u03b2 mutations associated with defects in immunity and peripheral tolerance. J Exp Med. 2019;216(6):1311\u201327.","journal-title":"J Exp Med"},{"issue":"2","key":"3623_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.immuni.2010.08.004","volume":"33","author":"TR Malek","year":"2010","unstructured":"Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010;33(2):153\u201365.","journal-title":"Immunity"},{"key":"3623_CR26","doi-asserted-by":"crossref","unstructured":"Paliard, X., et al., Simultaneous production of IL-2, IL-4, and IFN-gamma by activated huma n CD4+ and CD8+ T cell clones. Journal of immunology (Baltimore, Md. : 1950), 1988. 141(3): p. 849\u201355.","DOI":"10.4049\/jimmunol.141.3.849"},{"key":"3623_CR27","doi-asserted-by":"crossref","unstructured":"Siegel, J.P., et al., The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science (New York, N.Y.), 1987. 238(4823): p. 75\u20138.","DOI":"10.1126\/science.3116668"},{"issue":"2","key":"3623_CR28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12185-017-2386-y","volume":"107","author":"K Matsuoka","year":"2018","unstructured":"Matsuoka K. Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives. Int J Hematol. 2018;107(2):130\u20137.","journal-title":"Int J Hematol"},{"key":"3623_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.coi.2019.07.003","volume":"61","author":"A Ballesteros-Tato","year":"2019","unstructured":"Ballesteros-Tato A, Papillion A. Mechanisms of action of low-dose IL-2 restoration therapies in SLE. Curr Opin Immunol. 2019;61:39\u201345.","journal-title":"Curr Opin Immunol"},{"key":"3623_CR30","doi-asserted-by":"crossref","unstructured":"Khoryati, L., et al., An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice. Sci Immunol, 2020. 5(50).","DOI":"10.1126\/sciimmunol.aba5264"},{"key":"3623_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.clim.2018.11.002","volume":"206","author":"M Mizui","year":"2019","unstructured":"Mizui M. Natural and modified IL-2 for the treatment of cancer and autoimmune diseases. Clin Immunol. 2019;206:63\u201370.","journal-title":"Clin Immunol"},{"issue":"5","key":"3623_CR32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nri3823","volume":"15","author":"D Klatzmann","year":"2015","unstructured":"Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015;15(5):283\u201394.","journal-title":"Nat Rev Immunol"},{"key":"3623_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/9056173","volume":"2018","author":"H Choudhry","year":"2018","unstructured":"Choudhry H, et al. Prospects of IL-2 in Cancer Immunotherapy. Biomed Res Int. 2018;2018:1\u20137.","journal-title":"Biomed Res Int"},{"issue":"10","key":"3623_CR34","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","volume":"22","author":"R Thomas Malek","year":"2022","unstructured":"Thomas Malek R, et al. Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nat Rev Immunol. 2022;22(10):614\u201328.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3623_CR35","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.1038\/s41467-019-11782-w","volume":"10","author":"Z Sun","year":"2019","unstructured":"Sun Z, et al. A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8(+) T-cell response and effective tumor control. Nat Commun. 2019;10(1):3874.","journal-title":"Nat Commun"},{"issue":"2","key":"3623_CR36","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201948052","volume":"21","author":"AC Court","year":"2020","unstructured":"Court AC, et al. Mitochondrial transfer from MSCs to T cells induces Treg differentiation and restricts inflammatory response. EMBO Rep. 2020;21(2): e48052.","journal-title":"EMBO Rep"},{"issue":"7873","key":"3623_CR37","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583\u20139.","journal-title":"Nature"},{"key":"3623_CR38","first-page":"1","volume":"2018","author":"C Liu","year":"2018","unstructured":"Liu C, et al. Mesenchymal Stem Cells Promote the Osteogenesis in Collagen-Induced Arthritic Mice through the Inhibition of TNF-\u03b1. Stem Cells International. 2018;2018:1\u201310.","journal-title":"Stem Cells International"},{"issue":"6","key":"3623_CR39","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2144\/000113418","volume":"48","author":"AV Bryksin","year":"2010","unstructured":"Bryksin AV, Matsumura I. Overlap extension PCR cloning: a simple and reliable way to create rec ombinant plasmids. Biotechniques. 2010;48(6):463\u20135.","journal-title":"Biotechniques"},{"key":"3623_CR40","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-1-4939-3271-9_8","volume":"1382","author":"MJ Benskey","year":"2016","unstructured":"Benskey MJ, Manfredsson FP. Lentivirus Production and Purification. Methods Mol Biol. 2016;1382:107\u201314.","journal-title":"Methods Mol Biol"},{"key":"3623_CR41","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1146\/annurev-immunol-042617-053352","volume":"36","author":"SH Ross","year":"2018","unstructured":"Ross SH, Cantrell DA. Signaling and Function of Interleukin-2 in T Lymphocytes. Annu Rev Immunol. 2018;36:411\u201333.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"3623_CR42","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/cei.13422","volume":"200","author":"SL McQuaid","year":"2020","unstructured":"McQuaid SL, et al. Low-dose IL-2 induces CD56(bright) NK regulation of T cells via NKp44 and NKp46. Clin Exp Immunol. 2020;200(3):228\u201341.","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"3623_CR43","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1089\/hum.2018.054","volume":"30","author":"S Bougioukli","year":"2019","unstructured":"Bougioukli S, et al. Lentiviral Gene Therapy for Bone Repair Using Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells. Hum Gene Ther. 2019;30(7):906\u201317.","journal-title":"Hum Gene Ther"},{"issue":"23\u201324","key":"3623_CR44","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1089\/hum.2022.117","volume":"33","author":"K Collon","year":"2022","unstructured":"Collon K, et al. Improving Lentiviral Transduction of Human Adipose-Derived Mesenchymal Stem Cells. Hum Gene Ther. 2022;33(23\u201324):1260\u20138.","journal-title":"Hum Gene Ther"},{"key":"3623_CR45","doi-asserted-by":"crossref","unstructured":"Li, Y.J. and Z. Chen, Cell-based therapies for rheumatoid arthritis: opportunities and challenges. Ther Adv Musculoskelet Dis, 2022. 14: p. 1759720X221100294.","DOI":"10.1177\/1759720X221100294"},{"issue":"7","key":"3623_CR46","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","volume":"17","author":"MB Atkins","year":"1999","unstructured":"Atkins MB, et al. High-dose recombinant interleukin 2 therapy for patients with metastat ic melanoma: analysis of 270 patients treated between 1985 and 1993. Journal of clinical oncology\u202f: official journal of the American Societ y of Clinical Oncology. 1999;17(7):2105\u201316.","journal-title":"Journal of clinical oncology : official journal of the American Societ y of Clinical Oncology"},{"issue":"3","key":"3623_CR47","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","volume":"13","author":"G Fyfe","year":"1997","unstructured":"Fyfe G, et al. Results of treatment of 255 patients with metastatic renal cell carcin oma who received high-dose recombinant interleukin-2 therapy. Journal of clinical oncology\u202f: official journal of the American Societ y of Clinical Oncology. 1997;13(3):688\u201396.","journal-title":"Journal of clinical oncology : official journal of the American Societ y of Clinical Oncology"},{"key":"3623_CR48","doi-asserted-by":"publisher","first-page":"648408","DOI":"10.3389\/fimmu.2021.648408","volume":"12","author":"H Gra\u00dfhoff","year":"2021","unstructured":"Gra\u00dfhoff H, et al. Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases. Front Immunol. 2021;12:648408\u2013648408.","journal-title":"Front Immunol"},{"key":"3623_CR49","doi-asserted-by":"publisher","first-page":"1344917","DOI":"10.3389\/fendo.2024.1344917","volume":"15","author":"Y Lu","year":"2024","unstructured":"Lu Y, et al. Unraveling the genetic basis of the causal association between inflammatory cytokines and osteonecrosis. Front Endocrinol (Lausanne). 2024;15:1344917.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"3623_CR50","doi-asserted-by":"publisher","first-page":"624","DOI":"10.4314\/ahs.v23i3.73","volume":"23","author":"J Wang","year":"2023","unstructured":"Wang J, Liu J. Correlation between protein expression profiling of inflammation and bone metabolism in rheumatoid arthritis patients. Afr Health Sci. 2023;23(3):624\u201334.","journal-title":"Afr Health Sci"},{"issue":"3","key":"3623_CR51","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1084\/jem.163.3.550","volume":"163","author":"M Fujii","year":"1986","unstructured":"Fujii M, et al. High-affinity receptor-mediated internalization and degradation of interleukin 2 in human T cells. J Exp Med. 1986;163(3):550\u201362.","journal-title":"J Exp Med"},{"issue":"3","key":"3623_CR52","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/08830185.2023.2274574","volume":"43","author":"R Zhang","year":"2024","unstructured":"Zhang R, et al. Low-dose IL-2 therapy in autoimmune diseases: An update review. Int Rev Immunol. 2024;43(3):113\u201337.","journal-title":"Int Rev Immunol"},{"key":"3623_CR53","doi-asserted-by":"publisher","first-page":"1359041","DOI":"10.3389\/fimmu.2024.1359041","volume":"15","author":"SX Zhang","year":"2024","unstructured":"Zhang SX, et al. The efficacy and safety of short-term and low-dose IL-2 combined with tocilizumab to treat rheumatoid arthritis. Front Immunol. 2024;15:1359041.","journal-title":"Front Immunol"},{"issue":"3","key":"3623_CR54","volume":"16","author":"MF Riaz","year":"2024","unstructured":"Riaz MF, et al. Comparison of Low-Dose Interleukin 2 Therapy in Conjunction With Standard Therapy in Patients With Systemic Lupus Erythematosus vs Rheumatoid Arthritis: A Systematic Review. Cureus. 2024;16(3): e56704.","journal-title":"Cureus"},{"issue":"1","key":"3623_CR55","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1182\/blood-2016-02-702852","volume":"128","author":"J Koreth","year":"2016","unstructured":"Koreth J, et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016;128(1):130\u20137.","journal-title":"Blood"},{"key":"3623_CR56","doi-asserted-by":"crossref","unstructured":"Boyman, O., et al., Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science (New York, N.Y.), 2006. 311(5769): p. 1924\u20137.","DOI":"10.1126\/science.1122927"},{"key":"3623_CR57","doi-asserted-by":"crossref","unstructured":"Ward, N.C., et al., IL-2\/CD25: A Long-Acting Fusion Protein That Promotes Immune Tolerance by Selectively Targeting the IL-2 Receptor on Regulatory T Cells. Journal of immunology (Baltimore, Md. : 1950), 2018. 201(9): p. 2579\u20132592.","DOI":"10.4049\/jimmunol.1800907"},{"key":"3623_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100103","volume":"4","author":"N Dixit","year":"2021","unstructured":"Dixit N, et al. NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. Journal of Translational Autoimmunity. 2021;4: 100103.","journal-title":"Journal of Translational Autoimmunity"},{"issue":"1","key":"3623_CR59","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12026-017-8973-4","volume":"66","author":"M Khosravi","year":"2018","unstructured":"Khosravi M, et al. Induction of CD4(+)CD25(+)Foxp3(+) regulatory T cells by mesenchymal stem cells is associated with RUNX complex factors. Immunol Res. 2018;66(1):207\u201318.","journal-title":"Immunol Res"},{"issue":"1","key":"3623_CR60","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s13287-018-0991-1","volume":"9","author":"M Khosravi","year":"2018","unstructured":"Khosravi M, et al. Induction of CD4(+)CD25(+)FOXP3(+) regulatory T cells by mesenchymal stem cells is associated with modulation of ubiquitination factors and TSDR demethylation. Stem Cell Res Ther. 2018;9(1):273.","journal-title":"Stem Cell Res Ther"},{"issue":"8","key":"3623_CR61","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/cbin.12171","volume":"48","author":"S Zargarani","year":"2024","unstructured":"Zargarani S, et al. Adipose-derived mesenchymal stem cells ameliorates experimental autoimmune encephalomyelitis via modulation of Th1\/Th17 and expansion of Th2\/Treg responses. Cell Biol Int. 2024;48(8):1124\u201337.","journal-title":"Cell Biol Int"},{"issue":"7","key":"3623_CR62","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/stcltm\/szad032","volume":"12","author":"Z Cao","year":"2023","unstructured":"Cao Z, et al. Allogenic Umbilical Cord-Derived Mesenchymal Stromal Cells Sustain Long-Term Therapeutic Efficacy Compared With Low-Dose Interleukin-2 in Systemic Lupus Erythematosus. Stem Cells Transl Med. 2023;12(7):431\u201343.","journal-title":"Stem Cells Transl Med"},{"issue":"2","key":"3623_CR63","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/rheumatology\/keu377","volume":"54","author":"OI Eseonu","year":"2015","unstructured":"Eseonu OI, De Bari C. Homing of mesenchymal stem cells: mechanistic or stochastic? Implications for targeted delivery in arthritis. Rheumatology (Oxford). 2015;54(2):210\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"3623_CR64","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4252\/wjsc.v6.i2.195","volume":"6","author":"T Nagamura-Inoue","year":"2014","unstructured":"Nagamura-Inoue T, He H. Umbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility. World J Stem Cells. 2014;6(2):195\u2013202.","journal-title":"World J Stem Cells"},{"key":"3623_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2023.104771","volume":"393\u2013394","author":"S Dehnavi","year":"2023","unstructured":"Dehnavi S, et al. Interactions of mesenchymal stromal\/stem cells and immune cells following MSC-based therapeutic approaches in rheumatoid arthritis. Cell Immunol. 2023;393\u2013394: 104771.","journal-title":"Cell Immunol"},{"issue":"6","key":"3623_CR66","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3109\/14653249.2010.542456","volume":"13","author":"R Tatara","year":"2011","unstructured":"Tatara R, et al. Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation. Cytotherapy. 2011;13(6):686\u201394.","journal-title":"Cytotherapy"},{"issue":"1","key":"3623_CR67","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-021-01037-x","volume":"14","author":"T Zhou","year":"2021","unstructured":"Zhou T, et al. Challenges and advances in clinical applications of mesenchymal stromal cells. J Hematol Oncol. 2021;14(1):24.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"3623_CR68","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.4252\/wjsc.v13.i12.1845","volume":"13","author":"MS Choudhery","year":"2021","unstructured":"Choudhery MS. Strategies to improve regenerative potential of mesenchymal stem cells. World J Stem Cells. 2021;13(12):1845\u201362.","journal-title":"World J Stem Cells"},{"key":"3623_CR69","doi-asserted-by":"crossref","unstructured":"Olmedo-Moreno, L., et al., Heterogeneity of In Vitro Expanded Mesenchymal Stromal Cells and Strategies to Improve Their Therapeutic Actions. Pharmaceutics, 2022. 14(5).","DOI":"10.3390\/pharmaceutics14051112"},{"key":"3623_CR70","doi-asserted-by":"crossref","unstructured":"Sarsenova, M., et al., Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis. Int J Mol Sci, 2021. 22(21).","DOI":"10.3390\/ijms222111592"},{"issue":"3","key":"3623_CR71","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","volume":"20","author":"C Raffin","year":"2020","unstructured":"Raffin C, Vo LT, Bluestone JA. T(reg) cell-based therapies: challenges and perspectives. Nat Rev Immunol. 2020;20(3):158\u201372.","journal-title":"Nat Rev Immunol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03623-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03623-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03623-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:04:50Z","timestamp":1768341890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-025-03623-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3623"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03623-7","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"28 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments are carried out under the project license (No. 2020AE01061) approved by the Ethics Committee of Drum Tower Hospital, Nanjing Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}